Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks Consensus Estimate of 64 cents per share. Earnings rose 12% year over year.

The Case for Pfizer. Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Its growth prospects, particularly in oncology: As many big pharma companies do, Pfizer bought a smaller drug developer in 2023, Seagen (costing it $43 billion), acquiring its various drugs in ...

Sales in the U.S., where Pfizer's patent expired Nov. 30 for Lipitor, the top-selling drug in history, fell to $5.95 billion, from $7.02 billion. International sales edged up 1%, to $9.45 billion.